Clinical significance of serum and urinary soluble urokinase receptor (suPAR) in primary nephrotic syndrome and MPO-ANCA-associated glomerulonephritis in Japanese

Clinical and Experimental Nephrology

Volumn 19, Issue 5, 2015, Pages 804-814

  Fujimoto, Keiji ^a   Imura, Junko ^a   Atsumi, Hirokatsu ^a   Matsui, Yuki ^a   Adachi, Hiroki ^a   Okuyama, Hiroshi ^a   Yamaya, Hideki ^a   Yokoyama, Hitoshi ^a  

^a KANAZAWA MEDICAL UNIVERSITY   (Japan)

Author keywords

MPO ANCA associated glomerulonephritis; Nephrotic syndrome; suPAR

Indexed keywords

CYCLOSPORIN; METHYLPREDNISOLONE; PREDNISOLONE; UROKINASE RECEPTOR; IMMUNOSUPPRESSIVE AGENT; NEUTROPHIL CYTOPLASMIC ANTIBODY; PEROXIDASE; PLAUR PROTEIN, HUMAN;

ADULT; AGED; ANTINEUTROPHIL CYTOPLASMIC ANTIBODY POSITIVE GLOMERULONEPHRITIS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FOCAL GLOMERULOSCLEROSIS; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JAPANESE (PEOPLE); MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; MINIMAL CHANGE NEPHROTIC SYNDROME; NEPHROTIC SYNDROME; PRIMARY NEPHROTIC SYNDROME; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; PROTEINURIA; TREATMENT RESPONSE; ASIAN CONTINENTAL ANCESTRY GROUP; COHORT ANALYSIS; DISEASE COURSE; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY;

ADULT; AGED; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ASIAN CONTINENTAL ANCESTRY GROUP; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; GLOMERULONEPHRITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; NEPHROTIC SYNDROME; PEROXIDASE; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RETROSPECTIVE STUDIES;

EID: 84944159038     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-014-1067-x     Document Type: Article

References (19)

1. Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med. 2011;17:952–60.
2. Wei C, Moller CC, Altintas MM, Li J, Schwarz K, Zacchigna S, et al. Modification of kidney barrier function by the urokinase receptor. Nat Med. 2008;14:55–63.
3. Wei C, Trachtman H, Li J, Dong C, Friedman AL, Gassman JJ, et al. Circulating suPAR in two cohorts of primary FSGS. J Am Soc Nephrol. 2012;23:2051–9.
4. Huang J, Liu G, Zhang YM, Cui Z, Wang F, Liu XJ, et al. Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis. Kidney Int. 2013;84:366–72.
5. Huang J, Liu G, Zhang YM, Cui Z, Wang F, Liu XJ, et al. Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis. BMC Med. 2014;12:81. doi:10.1186/1741-7015-12-81.
6. Sinha A, Bajpai J, Saini S, Bhatia D, Gupta A, Puraswani M, et al. Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children. Kidney Int. 2014;85(3):649–58.
7. Meijers B, Maas RJH, Sprangers B, Claes K, Poesen R, Bammens B, et al. The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. Kidney Int. 2014;85:636–40.
8. Wada T, Nangaku M, Maruyama S, Imai E, Shoji K, Kato S, et al. A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease. Kidney Int. 2014;85:641–8.
9. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.
10. The Japanese Society of Nephrology. Guidelines for the treatment of nephrotic syndrome. Nihon Jinzo Gakkai Shi. 2011;53:78–122.
11. The Japanese Society of Nephrology. Guidelines for the treatment of rapidly progressive glomerulonephritis. Nihon Jinzo Gakkai Shi. 2011;53:509–55.
12. Maas RJ, Wetzels JF, Deegens JK. Serum-soluble urokinase receptor concentration in primary FSGS. Kidney Int. 2012;81:1043–4.
13. Maas RJ, Deegens JK, Wetzels JF. Serum suPAR in patients with FSGS: trash or treasure? Prediatr Nephrol. 2013;28:1041–8.
14. Zang B, Shi W, Ma J, Sloan A, Faul C, Wei C, et al. The calcineurin-NFAT pathway allows for urokinase receptor-mediated β3 integrin signaling to cause podocyte injury. J. Mol. Med. (Berl.). 2012;90:1407–20.
15. Bock ME, Price H, Gallon L, Langman CB. Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: A single-center reports. Clin Am Soc Nephrol. 2013;8:1304–11.
16. Backes Y, van der Sluijs KF, Mackie DP, Tacke F, Koch A, Tenhunen JJ, et al. Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review. Intensive Care Med. 2012;38:1418–28.
17. Koch A, Voigt S, Kruschinski C, Sanson E, Duckers H, Horn A, et al. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care. 2011;15:R63.
18. Yilmaz G, Koksal I, Karahan SC, Mentese A. The diagnostic and prognostic significance of soluble urokinase plasminogen activator receptor in systematic inflammatory response syndrome. Clin Biochem. 2011;44:1227–30.
19. 3 integrin upregulation in rapidly progressive glomerulonephritis. Nephrol Dial Transplant. 1995;10:1155–61.